Clinical trialsCompany release

Clearmind completes Part C enrolment in CMND-100 alcohol use disorder trial

Clearmind Medicine Inc. (CMND) · Mon 16 Nov 2026

The company says recruitment is finished for the randomised, placebo-controlled multiple-dose part of its Phase I/IIa study of a non-hallucinogenic psychedelic-derived candidate.

Clearmind Medicine announced on 16 November 2026 that it has completed patient enrolment in Part C of its Phase I/IIa clinical trial of CMND-100, a candidate for alcohol use disorder (AUD). The company describes the compound as non-hallucinogenic and derived from psychedelic chemistry.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Clearmind Medicine Inc. ↗

Article written by VigiEye from the official source (Clearmind Medicine Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →